Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Medical Update Online > All Medical News > Conference Highlights > Nuvectis Pharma will present clinical and preclinical findings for NXP900 at AACR-NCI-EORTC 2025

Advertisment

Nuvectis Pharma will present clinical and preclinical findings for NXP900 at AACR-NCI-EORTC 2025

Written by | 19 Oct 2025 | Conference Highlights

Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.

Titles and Presenters Presentation Details
Title
Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900

Presenter
Gerald Falchook, MD
Sarah Cannon Research Institute at HealthOne
Denver, CO, United States.

 Session
Poster Session A

Poster Number
LB-A019

Session Date / Time
October 23, 2025
12:30 – 4 pm ET
Title
NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, potently inhibits tumor growth in FAT1 mutated xenograft models

Presenter
Asier Unciti-Broceta
University of Edinburgh
Edinburgh, United Kingdom

 Session
Poster Session A

Poster Number
A099

Session Date / Time
October 23, 2025
12:30 – 4 pm ET

 

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.